Article

"Dirty Dish" Hypothesis May Hold Water for Gout

Management of hyperuricemia in gout with a 2-stage approach based on the "dirty dish" hypothesis could be effective.

Management of hyperuricemia in gout with a 2-stage approach based on the "dirty dish" hypothesis could be effective. The first stage would consist of a period of crystal depletion, with the target serum urate level far below the threshold for saturation of urate (lower than 6 mg/dL) to completely dissolve formed crystals; the second stage would involve a preventive treatment period in which the target is a serum urate level just below that threshold for saturation of urate to avoid new crystal formation.

Perez-Ruiz and colleagues conducted a prospective cohort study of 211 patients. Serum urate levels were measured at baseline and at the time of urate-lowering therapy withdrawal. Recurrence and several variables were analyzed.

Serum urate levels during urate-lowering treatment and after its withdrawal were independently related to gout recurrence; they were 8.8 ± 1.3 mg/dL, 4.9 ± 0.9 mg/dL, and 8.5 ± 1.4 mg/dL at baseline, during urate-lowering therapy, and after withdrawal of urate-lowering therapy, respectively. There was no crystal-proven recurrence of gout in the patients who had average serum urate levels lower than 7 mg/dL after urate-lowering therapy withdrawal.

The authors made an analogy with the cleaning of a dirty dish: more is required to get it clean than to keep it clean.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.